Teva Pharmaceutical Industries Limited Stock

Equities

TEVA

US8816242098

Pharmaceuticals

Real-time Estimate Cboe BZX 15:14:48 2024-04-16 EDT 5-day change 1st Jan Change
13.14 USD -0.72% Intraday chart for Teva Pharmaceutical Industries Limited -5.73% +26.15%
Sales 2024 * 15.86B 21.9B Sales 2025 * 16.35B 22.57B Capitalization 14.83B 20.48B
Net income 2024 * 1.54B 2.12B Net income 2025 * 1.44B 1.99B EV / Sales 2024 * 1.86 x
Net Debt 2024 * 14.62B 20.19B Net Debt 2025 * 12.12B 16.73B EV / Sales 2025 * 1.65 x
P/E ratio 2024 *
10.6 x
P/E ratio 2025 *
9.89 x
Employees 35,737
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.57%
More Fundamentals * Assessed data
Dynamic Chart
Teva Pharmaceutical Unit Says Late-Stage Trial in China of Ajovy to Prevent Migraine Achieves Primary, Secondary Endpoints MT
Teva Confirms Efficacy and Safety of AJOVY for the Prevention of Migraine with Results from Phase 3 Trial in China CI
Teva Pharmaceuticals International, mAbxience Sign Licensing Deal for Oncology Biosimilar Candidate MT
UroGen Pharma Sues Teva Pharmaceuticals Over Alleged Patent Infringement of Jelmyto MT
US Appellate Court Vacates Ruling Maintaining Johnson & Johnson's Schizophrenia Drug Patent; Sends Back for Review MT
US Appellate Court Vacates Ruling Maintaining Johnson & Johnson's Schizophrenia Drug Patent; Sends Back for Review MT
Teva Pharmaceutical to Get $150 Million From Carlyle Group's Abingworth for Asthma Therapy With Launch Therapeutics MT
JPMorgan Upgrades Teva Pharmaceutical Industries to Neutral From Underweight, Adjusts Price Target to $14 From $11 MT
Teva Pharmaceutical Industries Insider Sold Shares Worth $657,240, According to a Recent SEC Filing MT
Teva Pharmaceutical Industries Insider Sold Shares Worth $1,048,119, According to a Recent SEC Filing MT
Teva Pharmaceutical Industries Insider Sold Shares Worth $1,352,090, According to a Recent SEC Filing MT
Teva Pharmaceutical Industries Insider Sold Shares Worth $414,270, According to a Recent SEC Filing MT
Teva Pharmaceutical Industries Insider Sold Shares Worth $1,277,207, According to a Recent SEC Filing MT
Teva Pharmaceutical Industries Insider Sold Shares Worth $270,176, According to a Recent SEC Filing MT
Global markets live: Domino's Pizza, Walt Disney, Broadcom, Ryanair, Exxon Mobil, Goldman Sachs... Our Logo
More news

Latest transcript on Teva Pharmaceutical Industries Limited

1 day-0.64%
1 week-5.73%
Current month-6.66%
1 month-1.13%
3 months+19.73%
6 months+50.69%
Current year+26.15%
More quotes
1 week
13.06
Extreme 13.06
14.00
1 month
13.06
Extreme 13.06
14.47
Current year
10.45
Extreme 10.45
14.47
1 year
7.09
Extreme 7.085
14.47
3 years
6.78
Extreme 6.7791
14.47
5 years
6.07
Extreme 6.07
15.72
10 years
6.07
Extreme 6.07
72.31
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 22-12-31
Director of Finance/CFO 51 19-12-21
Chief Tech/Sci/R&D Officer - 22-07-31
Members of the board TitleAgeSince
Director/Board Member 77 15-08-31
Director/Board Member 60 20-06-08
Chairman 76 14-12-31
More insiders
Date Price Change Volume
24-04-16 13.17 -0.45% 5 769 511
24-04-15 13.23 -0.53% 13,512,265
24-04-12 13.3 -4.11% 15,238,796
24-04-11 13.87 +0.14% 9,571,339
24-04-10 13.85 -0.86% 6,205,347

Delayed Quote Nyse, April 16, 2024 at 02:59 pm

More quotes
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
13.23 USD
Average target price
15.74 USD
Spread / Average Target
+18.94%
Consensus